Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine in severe Alzheimer's disease
NCT00216593Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2003
- Primary completion
- Sep 2007
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of galantamine in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Dec 2003; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00216593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216593.